Keywords
Câncer pulmonar
Célula pequena
Célula não pequena
How to Cite
Abstract
Lung cancer is the second most common non-skin cancer and the leading cause of cancer death worldwide, a global health problem. This study aimed to investigate the challenges and advances in the treatment of lung cancer through a systematic review in the PubMEd database. Fifteen publications between 2021 and 2024 were selected. Ten addressed non-small cell lung cancer and five small cell lung cancer. Chemotherapy, immunotherapy, and targeted therapies have been suggested for both types of the disease. Treatment of non-small cell cancer includes genomic and proteomic profiling to identify potential targets, immune checkpoint inhibitors, understanding the biological basis of metastasis, surgery, personalized treatment plan. The challenges were identification of target genetic alterations, development of effective drugs and combinations, overcoming drug resistance, better biomanufacturers, toxicity, resistance to immune inhibitors, inequality in access to treatment. Small cell carcinoma can be treated with tyrosine inhibitors associated with immunotherapy, transporting drugs/genes to the site/target, identifying a specific target that is highly homogeneous and stably expressed in the tumor. The challenges were treatment abandonment, complexity of the disease, non-acceptance of disease progression. It was concluded that, despite numerous advances in the treatment of lung cancer, there is no standard, each patient needs individual adjustments. Communication between doctor and patient may be key to providing personalized anticancer therapy.
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2015;65:87-108.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220-233.
Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy. MedComm. 2021;2:692-729.
Altaf R, Jadoon SS, Muhammad SA, Ilyas U, Duan Y. Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Front Oncol. 2022;12:1-10.
Guo H, Zhang J, Qin C, Yan H, Luo X, Zhou H. Advances and challenges of first-line
immunotherapy for non-small cell lung cancer. A review. Medicine. 2024;103(3):1-14.
Barr T, Ma S, Li Z, Yu J. Recent advances and remaining challenges in lung cancer therapy. Chinese Med J. 2024;137(5):533-546.
Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 2019;5:1749–1768.
Cardoso RC, Carlo MMRP. Fadiga em pacientes com câncer de pulmão: uma revisão sistemática de literatura. Rev Bras Cancerol. 2013;59(4):575-582.
Houda I, Dickhoff C, Groot CAU, Damhuis RAM, Reguart N, Provencio M et al. Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. Lancet Reg Health. 2024;38:1-18.
Kästner A, Kron A, Berg Nvd, Moon K, Scheffer M, Schilinger G et al. Evaluation of the effectiveness of a nationwide precision medicine program for patients with dvanced non-small cell lung cancer in Germany: a historical cohort analysis. Lancet Reg Health. 2024;36:1-13.
Araghi M, Mannai R, Maleki AH, Hamidi A, Rostami S, Safa SH et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(162):1-26.
Bayram E, Toyran T, Güney B, Uguz AH, Gümürdülü D, Paydas S. Issues with the targeted therapy of non-small cell lung cancer with thyroid metastases: A case report. Medicine Int. 2023;3(6):1-5.
Kim S-J, Puranik N, Yadav D, Jin J-O, Lee PCW. Lipid nanocarrier-based drug delivery systems: therapeutic advances in the treatment of lung cancer. Int J Nanomedicene. 2023;18:2659-2676.
Orstad S, Øystein F, Madebo T, Gulbrandsen P, Strand R, Lindemark F et al. “The challenge in the complexity” – A qualitative study about decision-making in advanced lung cancer treatment. Lung Cancer. 2023;183:1-8.
Vicidomini G. Current challenges and future advances in lung cancer: genetics, instrumental diagnosis and treatment. Cancers (Basel). 2023;15(14):1-6.
Rivera-Concepcion J, Uprety D, Adjei AA. Challenges in the use of targeted therapies in non-small cell lung cancer. Cancer Res Treat. 2022;54(2):315-329.
Gopal V, Dubashi B, Kayal S, Penumadu P, Rajaram M, Karunanithi G et al. Challenges in the management of lung cancer: real-world experience from a tertiary center in South India. South Asian J Cancer. 2021;10:175-182.
Wang B, Guo H, Xu H, Yu H, Chen Y, Zhao G. Research progress and challenges in the treatment of central nervous system metastasis of non-small cell lung cancer. Cells. 2021;10:1-19.
Xie S, Wu Z, Qi Y, Wu B, Zhu Z. The metastasizing of lung cancer: recent advances and therapeutic challenges. Biomed Pharmacother. 2021;138:1-18.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Juliana Gorgulho Campos Gontijo, Ana Clara Rezende Freitas, Gustavo Souza Gontijo Garcia